semaglutide and pots A newly published case series reports that GLP-1 receptor agonists (like semaglutide Résumé de l’article “Significant improvement

It was applied as a topical spray a simple, non-invasive daily application

Safety Concerns Documented risks include: Contamination risk with multiple pen entries Dosing errors more likely with complex regimens 55% of microdosers self-medicate without medical supervision Use of non-FDA approved compounded formulations 22% regret rate among microdosers Mathematical Modeling: What the Numbers Say Pharmacokinetic Simulations Recent mathematical models using real-world pharmacokinetic data reveal: *Theoretical efficacy based on area under curve (AUC) maintenance Key Modeling Insights Diminishing returns: Daily dosing provides minimal additional benefit over 3x weekly Efficacy threshold: Models suggest 75% efficacy retention even with daily microdosing Individual variation: Fast metabolizers may benefit more from split dosing Dose adjustment needed: Total weekly dose may need 10-20% increase with microdosing Open-source availability: Researchers have made pharmacokinetic models publicly available at GitHub (seanlawley/glp1) for those interested in exploring dosing optimization strategies

Lots of them have minimal research, and some need to be carefully formulated in order to penetrate the skin and be effective

Food and Drug Administration in connection with Ozempic, Rybelsus, Wegovy, Trulicity, and Mounjaro

The most commonly observed autoimmune issues included: Ulcerative colitis Autoimmune thyroiditis Rheumatoid arthritis Psoriasis Ankylosing spondylitis The risks were modest but consistentraising questions about whether weight loss jabs could trigger autoimmune disease in people who are genetically or environmentally susceptible